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Abstract
Background:  Changes in the balance of decidual leucocyte populations may lead to an
unfavourable uterine microenvironment which may be associated with the development of
preeclampsia (PE). In this study, we therefore investigated the leucocyte subpopulations in decidual
tissues of 33 women with preeclampsia and 66 control patients.
Methods: Decidua was either obtained via curettage during cesarean section or dissected from
the surface of the basal plate of the placenta after spontaneous delivery. We used FACS analysis to
quantify decidual leukocytes (CD45), NK cells (CD56+/CD16+ and CD56++/CD16-), antigen
presenting cells (HLA-DR, DC-Sign, CD14) and T/B cells (CD8, CD4, alpha-beta-T-cell receptor,
gamma-delta-T-cell receptor, CD25, CD19).
Results: The number of decidual cytotoxic CD8+T-lymphocytes (P < 0.02), alpha-beta -T-cell
receptor positive T cells (P < 0.03) and of CD56+/CD16+ NK cells (P < 0.03) was lower in decidua
from women with PE than in decidua from control patients.
Conclusion:  The observed reduction of specific leucocyte subsets could create a
microenvironment which is unfavourable for an appropriate placentation and could thereby be
involved in the development of preeclamptic symptoms.
Background
Preeclampsia (PE) is a major clinical problem occuring in
about 5% of all pregnancies. It is often linked to high
maternal and perinatal mortality and morbidity even in
highly developed countries [1]. To date, iatrogenic
induced delivery is still the only causal therapy.
The reasons for the development of PE are not yet com-
pletely understood. However, there is increasing evidence
that immunologic incompatibilities between the mother
and the developing placenta may play a major role: Mul-
tiparity and longer exposition to paternal semen prior to
conception are known to decrease the risk of developing
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PE [2,3]. Furthermore, there is a higher risk for PE if there
is short or missing preceding sperm contact, e.g. in the
case of donor insemination. The same holds true for cer-
tain combinations of maternal and paternal antigens or if
a women opts for a surrogate mother [1,4].
It is assumed that PE can be divided into two stages: The
first stage comprises the time of placentation in the first
half of pregnancy. It is characterized by a deficient inva-
sion of extravillous trophoblasts; patients are mostly
asymptomatic during this time. The second stage of PE is
found in the second half of pregnancy. Due to placental
oxidative stress and inflammation, mediators like soluble
fms-like tyrosine kinase 1 (sFlt-1) are secreted leading to
an enhanced maternal systemic inflammatory reaction
which may ultimately cause the clinical signs of PE such
as hypertension and proteinuria [5].
Human endometrium and pregnancy decidua harbour a
wide variety of CD45+immunocompetent cells. Within
that population, uterine natural killer (uNK) cells (CD3-,
CD16-, CD56++) form the main subpopulation [6]. They
accumulate during early pregnancy in the area of implan-
tation and are accompanied by trophoblast invasion,
which suggests that uNK cells are important for a success-
ful gestation [7]. Nevertheless, the role these cells play
during the development of PE is still unkown.
It has been suggested that uNK cells could contribute to
the development of PE by inducing the lysis of trophob-
last cells lacking HLA-G which could prevent an invasion
of the trophoblast cells which is deep enough for a suffi-
cient supply of the developing placenta with oxygen and
nutrients [8,9]. More recently this hypothesis has been
challenged by studies which showed that uNK are scarcely
cytotoxic and that moreover the expression of HLA-G may
be of little importance in the protection against lysis by
NK cells [10-12].
Uterine NK cells are known to express killer immunoglob-
ulin-like receptors (KIR) which may deliver inhibitory or
activating signals. HLA-C - like HLA-G and HLA-E -
expressed in trophoblast cells, is the dominant ligand for
these receptors. It has recently been shown that some
combinations of KIR on uterine NK cells and fetal HLA-C
molecules may be unfavourable to trophoblast cell inva-
sion and therby increase the risk of developing PE [13].
Uterine NK cells may also play a pivotal role in angiogen-
esis and artery remodelling at the feto-maternal interface
by producing several cytokines like IL-8 and VEGF
[14,15].
Another predominant cell type of the maternal immune
system that can be found when quantifying decidual
immune cells are CD3+ T cells [16]. T cells account for
about 10% of the decidual leukocyte population. They are
able to differentiate into a Th1 and Th2 type which both
secrete different patterns of cytokines. Due to the specific
hormonal situation, there may be a trend towards Th2
cytokine secretion in pregnancy which seems to be
reduced in PE [17,18].
The general role that decidual T cells play during normal
pregnancy is still unknown. As increased levels of CD4+
and CD8+ T cells as well as a Th1 shift can be observed in
preeclamptic pregnancies, T-cells are thought to play an
important role in the development of PE by increasing the
systemic inflammatory response [19,20].
CD14+ mononuclear cells account for about 20% of the
endometrial leukocyte population. Most of them express
HLA-DR and DC-Sign (CD209), which is a marker for
immature dendritic cells (DCs) [6,21,22]. In contrast to
immature DCs, only a tiny amount of mature CD83+ DCs
are found in decidua [22,23]. A recent study has reported
an upregulated expression of DC-Sign in placentas of
patients with HELLP syndrome, whereas in patients with
PE or IUGR no difference has been found [24].
One of the hallmarks of a successful human pregnancy is
the proper invasion of the placental trophoblasts into the
uterine wall. Up to now the regulation of this process has
not been fully understood. However, the remarkably
dense population of leukocytes found in the placental bed
in direct contact to trophoblasts suggests that these cells
may play a role in promoting placentation. As the decidua
is seeded with a huge variety of immunocompetent cells,
changes in their population might be an early event in the
development of PE. In this prospective observational
study, we therefore compared the decidual immune cell
population of patients with PE and control.
Methods
Patients
The study was designed as a prospective observational
study. Patients were recruited between 2003 and 2007 at
the department of obstetrics and gynecology, University
of Würzburg. Our investigations were approved by the
local ethics committee. Inclusion criteria for the PE group
were blood pressure ≥ 140/90 mmHg observed after 20
weeks of gestation and a significant proteinuria of ≥ 300
mg/24 h [25]. Inclusion criteria for the control group were
blood pressure < 140/90 mmHg and the absence of pro-
teinuria. In the PE group, 23 patients suffered from early
PE (symptom manifestation before 34 weeks of gesta-
tion), 10 had late PE (symptom manifestation after 34
weeks of gestation) [26].
None of the patients included had previously known dia-
betes, chronic hypertension or any symptomatic infec-Reproductive Biology and Endocrinology 2009, 7:132 http://www.rbej.com/content/7/1/132
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tious disease. Patients of the control group with leukocyte
counts ≥ 15.000/μl and with C-reactive protein > 2,5 mg/
dl in maternal serum were excluded. All placentas were
examined by a pathologist. Only patients whose placenta
showed no signs of infection (chorioamnionitis) were
included.
The distribution pattern concerning the gestational age
was roughly the same in both groups. In both groups most
of the patients underwent caesarean section (91% PE
group vs. 86,4% control group). Fetal growth restriction
was detected in 45% of the PE group and in 12% in the
control group. The main characteristics of the two groups
are shown in table 1. As iatrogenic preterm delivery always
needs a clear indication, we show the reasons for preterm
delivery in the control group in table 2.
Isolation of cells
To obtain decidual tissue, mucosal surface was either
scraped off the uterine lumen via curettage during cesar-
ean section and/or dissected from the whole surface of the
basal plate of the placenta after spontaneous delivery. In
preceding experiments with tissue obtained from 12
women undergoing casarean section, we had verified that
both types of decidua collection revealed identical cell
populations when performed on the same patient (Table
3). When decidual tissue was available from curettage,
this tissue was pooled with the tissue derived from the
basal plate of the corresponding placenta and processed
as one sample.
For isolation of decidual cells, specimens were carefully
dissected free of attached placental and/or myometrial tis-
sue as well as all visible blood clots and then washed twice
in PBS. The total decidual tissue (1-7 g) was then minced
into fragments of approximately 1 mm3 and digested for
40 minutes at 37°C under slight agitation in PBS with 200
U/ml hyaluronidase, 1 mg/ml collagenase type Ia, 0.2 mg/
ml DNase I (2500 Kunitz U/mg) and 1 mg/ml bovine
serum albumin/fraction V (all: Sigma-Aldrich, Deisen-
hofen, Germany). The cell suspension obtained was fil-
tered through sterile stainless steel 50-μm wire mesh and
washed once in PBS. The mononuclear cell population
was then separated by centrifugation over a Leukocyte
density gradient (density 1077, PAA, Cölebe, Germany),
washed twice in PBS, resuspended at 106 cells/ml in PBS/
2% human immunoglobulin (Beriglobin, Behring, Mar-
burg, Germany) and used immediately for subsequent
FACS-analysis.
Cell labeling and FACS
Flow cytometry of isolated mononuclear decidual cells
was performed with directly fluorochrome-conjugated
monoclonal antibodies as listened in Table 4, and the cor-
responding isotype control (mixture of mouse IgG1,
IgG2a, IgG2b, all: Pharmingen, Heidelberg, Germany). 5
× 104 cells per sample were stained in a volume of 50 μl
with 5 μl of the appropriate antibody mixture for 30 min
on ice. All Phycoerythrin (PE)-labeled antibodies were
used in combination with CD45/FITC. Furthermore,
CD56/PE was stained in combination with CD16/FITC to
detect the classical NK cells. All incubation steps were fol-
lowed by a wash in cold PBS/0.1% fetal calf serum (FCS).
Stained cells were subsequently resuspended in 200 μl
PBS/0.1% FCS and then analyzed in a FACScan flow
cytometer (Becton-Dickinson, Heidelberg, Germany). A
total of 1 × 104 cells per sample were evaluated for specific
staining. Results were analyzed using the WinMDI-soft-
ware (Version 2.8, ©Joseph Trotter).
Statistical analysis
Cellular subtypes were quantified in relation to the total
number of CD45 cells detected, and this percentage was
compared by the two-tailed non-parametric Mann Whit-
ney U test, as the Kolmogorov-Smirnoff test for normality
indicated a non-normal distribution of data. P values <
0.05 were counted as significant.
Results
The following cell surface markers were investigated by
FACS analysis: CD45, CD56, CD14, HLA-DR, DC-Sign,
Table 1: Clinical data of the patients.
PE Control
Number of patients 33 66
Age 31 [27; 35] 30 [27; 34]
Gestational age 33 [29; 35] 34 [30; 37]
Birth weight 1530 [1015; 2200] 2000 [1434; 2669]
Caesarean sections (%) 90.9% 86.4%
Multiple gestation 2 26
Fetal growth restriction 45% 12%
This table shows the median age, gestational age at delivery and birth 
weight including 25 and 75% quartiles. The mode of delivery (rate of 
cesarean sections in percent) and the number of multiple gestations is 
also provided.
Table 2: Causes for preterm delivery in the control group 
(gestational age <34 weeks)
Indication N
Preterm labour (single) 20
Multiple gestation 12
Fetal distress 8
IUGR 6
Fetal abnormalities 2
Placenta praevia 2
Uterine rupture 1
Reasons for preterm delivery (<= 34 weeks gestation) in the control 
group. The reasons are presented based on declining frequency. Note 
that multiple answers are possible, e.g. most patients with multiple 
gestation were delivered for preterm labour.Reproductive Biology and Endocrinology 2009, 7:132 http://www.rbej.com/content/7/1/132
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CD25,  αβ-T-cell receptor, γδ-T- cell receptor, CD4,
CD11b, CD19, CD8, CD16 and CD16+/CD56+. A typical
FACS blot pattern is shown in Figure 1.
The median of the percentage of the cells detected by
FACS analysis was employed. The results are summarized
in Figure 2, 3, 4 &5.
Although a slighthly lower number of CD 45+ leukocytes
was detected in the decidua of the PE group (42.3%), this
was not significantly different from the result of the con-
trol group (49.8%; Figure 2). No significant difference
could be observed when patients with early PE (≤ 34
weeks of gestation, n = 23) and late preeclampsia (> 10
weeks of gestation, n = 10) were compared (not shown).
NK cells
The percentage of uNK cells (%CD56++/CD16- in isolated
CD45+ cells) did not differ significantly between the two
groups (44.6% control group vs 40.5% PE group),
Table 3: Comparison of the two methods of decidual cell preparation
Decidua (uterus) Decidua (placenta)
Antigen Median 1. Quart 2. Quart Median 1. Quart 2. Quart p
CD45 (of all cells) 46.1 21.2 54.7 34.0 24.7 41.3 n.s.
Marker on cells in % of CD45+ cells
CD56 52.3 47.3 59.8 42.0 38.9 73.2 n.s.
CD16 25.5 9.2 33.3 17.0 14.0 26.7 n.s.
CD56+/CD16+ 10.2 8.1 14.3 13.2 6 24.7 n.s.
CD56++/CD16- 40.9 36.3 52.1 33.4 24.1 38.3 n.s.
HLA-DR 24.2 20.6 32.1 26.4 13.1 30.7 n.s.
DC-Sign 8 6.8 12.1 5.9 3.0 14.7 n.s.
CD14 16.9 8.7 20.2 15.0 12.7 29.2 n.s.
CD8 27.0 23.5 33.5 28.8 23.5 34.9 n.s.
CD4 29.8 22.8 33.6 34.1 28.6 41.7 n.s.
αβ-T 37.5 33.0 45.0 40.5 32.1 46.1 n.s.
γδ-T 3.0 1.6 5.0 2.6 1.3 3.4 n.s.
CD25 5.1 2.7 6.8 3.2 1.9 6.0 n.s.
CD19 1.6 1.2 4 2.9 1.9 3.8 n.s.
Quart = Quartile; 1. Quart: 25%; 2. Quart: 75%. P-values were calculated by the Mann-Whitney-U-Test.
Median, quartiles and p-values of the cell populations examined by FAX analysis comparing decidua obtained from the uterine cavity via curettage 
and prepared from the placenta (n = 12 in both cases, gestational week: 33-39).
Decidua was obtained either via curettage during caesarean section (attachment site of the placenta plus adjacent decidua) or from the 
corresponding placenta via preparation of the visible decidua from the basal plate directly after delivery of the placenta. To reduce contamination 
with peripheral blood cells to a minimum, samples were carefully cleaned of all visible signs of peripheral blood through careful washing. Data are 
provided as median, quartiles and p-values. NS = difference statistically not significant.
Table 4: Monoclonal (mouse) antibodies used for FACS-analysis
Antigen Clone Isotype Conjugation Dilution Supplier
CD4 RPA-T4 IgG1 PE 1:20 BD-Ph
CD8 RPA-T8 IgG1 PE 1:20 BD-Ph
CD14 M5E2 IgG2a PE 1:20 BD-Ph
CD16 3G8 IgG1 PE + FITC 1:20 BD-Ph
CD19 HIB19 IgG1 PE 1:20 BD-Ph
CD25 B1.49.9 IgG2a PE 1:10 BC
CD45 HI30 IgG1 FITC 1:20 BD-Ph
CD56 B159 IgG1 PE 1:20 BD-Ph
Dc-Sign 120507 IgG2b PE 1:20 RD
HLA-DR TÜ36 IgG2b PE 1:20 BD-Ph
ab-T BMA031 IgG2b PE 1:10 BC
gd-T IMMU 510 IgG1 PE 1:10 BC
Antibodies used for flow cytometric analysis of isolated mononuclear decidual cells.
BC: Beckmann Coulter, Krefeld, Germany
BD-Ph: BD Biosciences - Pharmingen, Heidelberg, Germany
RD: R&D-Systems, Heidelberg, GermanyReproductive Biology and Endocrinology 2009, 7:132 http://www.rbej.com/content/7/1/132
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although a higher percentage was found in the PE group.
However, significantly more classical CD56+/CD16+ NK
cells were detected in the control group than in the PE
group (7.3% vs 5.3%, p < 0,02; Figure 3).
Antigen presenting cells
HLA-DR+ Antigen presenting cells including, DC-Sign+
immature dendritic cells and monocytes expressing
CD14, account for about 15% of all CD45+ decidual cells
and were found in lower numbers in the PE group than in
the control group, although the difference did not reach
statistical significance (Figure 4).
T-cells and B cells
We found a significantly higher proportion of CD8+ cyto-
toxic T cells in the control group than in the PE group
(28,8% vs 22,6%, p = 0,02) Similarly, there were also sig-
nificantly more αβ-T cells in the control group than in the
PE group (35,0% vs 28,1%, p = 0,03).
In contrast to that, the small number of γδ-T cells did not
differ between the groups (1,7% control group vs 1,4% PE
group). Neither was the difference between the CD4+ cells
in the control group (23,4%) and the PE group (19,9%)
significant.
The rate of CD25+ cells representing either regulatory T
cells or mature dendritic cells was similar in both groups
(control group 1,9%, PE group 1,8%).
CD19+ B cells were represented equally in both groups
(2,3%; Figure 5).
Discussion
Despite many efforts the mechanisms that cause the
development of pre-eclampsia have not yet been eluci-
dated. The great diversity of the different kinds of placen-
tation in the animal kingdom point to the fact that in vivo
models are of limited use for an understanding of the
pathological processes during human placentation
[27,28]. An inbuilt difficulty is that the potential immu-
nologic malfunction occurs during early pregnancy - a
period of time when the symptoms of PE are not yet
apparent. That means that one can only know whether an
individual person is suffering from PE when the above
mentioned immunologic malfunction has already
occurred. There is growing evidence that the clinical fea-
tures of PE are generated either by defective placentation
during early pregnancy and/or by a distinct increase in the
systemic inflammatory response in the second part of
pregnancy [29].
Example of a flow cytometric analysis of a patient at 28 weeks of gestation (control group) Figure 1
Example of a flow cytometric analysis of a patient at 28 weeks of gestation (control group).
CD56+/CD16+Reproductive Biology and Endocrinology 2009, 7:132 http://www.rbej.com/content/7/1/132
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In the present study we compared the decidual immune
cell populations in women suffering from PE with a con-
trol collective.
When comparing the whole cell mixture derived from the
decidual samples, we found that the overall number of
CD45+ leukocytes was reduced - though only not signifi-
cantly so in our study - in patients suffering from PE. This
finding seems to confirm the observation of Williams et
al. that the overall leukocyte population in the decidua of
preeclamptic women is reduced [30]. Since we were inter-
ested in the relative proportion of immune cells in rela-
tion to each other, we compared the leukocyte
subpopulation in relation to the total CD45 count of the
respective patient by flow cytometric double staining.
We found that the percentage of CD8+  and  αβ-T-cell
receptor positive T cells as well as that of classical CD16+/
CD56+ NK cells in relation to the number of CD45+ leuko-
cytes was significantly lower in the decidua of preeclamp-
tic patients than in the control group. Similarly, Wiliams
et al. demonstrated a significant reduction of CD8+ and of
CD56+  lymphocytes in the decidua of preeclamptic
patients by using immunohistochemistry [30]. This obser-
vation is rather surprising, since inflammation is thought
to be an important component of clinically manifest PE
[19,31].
However, there is evidence that an inflammatory environ-
ment is an important prerequisite for the invasion of
tumour cells into healthy tissue in several cancers [32,33].
As invasive trophoblasts share many features with tumour
cells, one could speculate if the diminished invasiveness
of trophoblasts associated with PE might be a conse-
quence of the lower inflammatory cell population in the
placental bed.
In contrast to that, Stallmach et al., using immunohisto-
chemistry, observed a significant increase in CD8+ decid-
ual T cells and Wilczyñski et al. found an increased
percentage both of CD8+/CD28+  T cells and CD16+/
CD56+ NK cells by FACS analysis in patients with PE
[34,35]. They compared the overall amount of the cell
populations and not - as we did - the relation to the total
leukocyte count (CD45+ cells) [35].
In our study the number of CD16-/CD56+ uNK cells did
not differ significantly in the PE and the control group.
Previous studies investigating this issue by immunohisto-
chemistry led to conflicting results: While Williams et al.
and Eide et al. found a reduction, Stallmach et al.
described an increase in uNK cells in cases of PE
[30,34,36].
In early pregnancy, a significant increase in CD14+, HLA-
DR+  and DC-Sign+- antigen presenting cells can be
observed [23]. Studies investigating the number of anti-
gen presenting cells in the decidua of preeclamptic
patients have shown divergent results: while two studies
found an increase, three described a decrease in the
number of macrophages [30,37-41].
Using immunohistochemistry, a recent study has revealed
that the expression of DC-SIGN+ cells is upregulated in
placentas of patients with HELLP syndrome [24]. In this
study, we found that the number of DC-SIGN+ immature
dendritic cells as well as CD14+ and HLA-DR+ antigen pre-
senting cells were identical in the PE and the control
group. This observation stands in contrast to a previous
study which detected an increased infiltration of the
decidua with both immature and mature dendritic cells in
cases of PE [42].
A possible explanation for the different results could lie in
the method used for the preparation of the tissue. In the
above mentioned studies placental bed biopsies were
obtained. Because of the invasiveness of this procedure, a
contamination of the probes with peripheral blood can-
not be excludued. This could result in a changed cell pop-
ulation. Placenta bed biopsies furthermore may contain a
considerable amount of myometrial tissue which is
known to contain a remarkably high number of antigen-
presenting cells (manuscript in preparation). In our study,
we separated the decidual tissue from the placental sur-
face after the delivery of the placenta and/or obtained it
via curettage of the uterine cavity. This method provides
minimum contamination with peripheral maternal blood
Box and whisker plots provide the median expression of  CD45 including quartiles Figure 2
Box and whisker plots provide the median expression 
of CD45 including quartiles. The percentage is given in 
relation to the total cell suspension as a whole. Preeclampsia 
group (PE): n = 33 patients; Control group: n = 66 patients.
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Box and whisker plots provide the median expression of CD56/CD16, CD56/CD16 and CD 16 including quartiles Figure 3
Box and whisker plots provide the median expression of CD56/CD16, CD56/CD16 and CD 16 including quar-
tiles. The percentage is given in relation the CD45+ cells. Preeclampsia group (PE): n = 33 patients; Control group: n = 66 
patients.
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Box and whisker plots provide the median expression of HLA-DR, DC-Sign and CD14 including quartiles Figure 4
Box and whisker plots provide the median expression of HLA-DR, DC-Sign and CD14 including quartiles. The 
percentage is given in relation the CD45+ cells. Preeclampsia group (PE): n = 33 patients; Control group: n = 66 patients.
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Box and whisker plots provide the median expression of CD8, αβ-T-cell receptor, CD4, γδ-T-cell receptor, CD25, CD19  including quartiles Figure 5
Box and whisker plots provide the median expression of CD8, αβ-T-cell receptor, CD4, γδ-T-cell receptor, 
CD25, CD19 including quartiles. The percentage is given in relation the CD45+ cells. Preeclampsia group (PE): n = 33 
patients; Control group: n = 66 patients.
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and therefore appears to actually reflect the real in vivo sit-
uation. Although the probes were meticulously cleaned
from debris, the possibility of contaminations with
peripheral blood can, however, not be completely elimi-
nated.
Another difference between our study and the studies we
mentioned above is that we used FACS analysis instead of
immunohistochemistry for the quantitative analysis of
the decidual cell populations. Both methods have their
advantages and their shortcomings: IHC shows the spatial
allocation of different cell types in the investigated tissue
and may provide evidence for specific cell-cell interac-
tions. On the other hand, FACS analysis is more accurate
in terms of quantitative analysis, allows the inclusion of
higher cell numbers into the calculation and has less inter-
observer bias.
Conclusion
In this prospective study we compared - in a relatively
large group of patients (33 patients in the PE group and 66
patients in the group without PE) - the number of various
immune cells within the decidua which might be involved
in the development of PE. We found that the number of
CD56++/CD16-uNK cells and DC-SIGN+ immature DCs
does not differ significantly between the groups, whereas
CD8+ and αβ-T-cells as well as CD56+/CD16+ NK cells
were found less frequently in the PE group. Further inves-
tigations are needed to specify the role of these cells in
physiological and pathological pregnancy.
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